pipette
ENEnglish

[18F]FET PET enables histopathology-validated detection of non-contrast-enhancing glioblastoma

R. Stürzl, Sabrina Viktoria Kirchleitner, J. Lorenz, K. J. Schmidbauer, V. Stöcklein, Stefanie Quach, L. Kaiser, S. Stöcklein, Adrian Jun Zounek, E. Barci, Isabelle von Polenz, J. Blobner, Tobias Greve, Matthias Brendel, P. Harter, V. C. Ruf, R. Rupprecht, F. Ringel, D. Kalasauskas, Markus J. Riemenschneider, N. Thon, Louisa von Baumgarten, Jörg‐Christian Tonn, Nathalie L. Albert

Revista con revisión por paresUso en el mundo real

En palabras de los autores

Abstract Accurate visualization of glioblastoma is essential for guiding biopsy, resection and radiotherapy. Contrast-enhanced MRI is routine in clinical practice, yet it can miss metabolically active tumor outside areas of blood-brain barrier disruption. In a histopathology-validated cohort with 472 tissue samples of 61 patients with IDH-wildtype glioblastoma, we show that O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET ([ 18 F]FET PET) depicts tumor tissue significantly better than contrast-enhanced MRI (CE-MRI), especially in regions that show no enhancement on MRI. [ 18 F]FET PET achieves substantially higher sensitivity for tumor detection (91.2% vs 52.6%) and maintains high reliability in non-enhancing tissue (positive predictive value 98.3%), findings that are consistent across newly diagnosed and recurrent disease and in both cohorts undergoing either resection or biopsy. These results indicate that [ 18 F]FET PET complements MRI by revealing MRI-occult tumor burden. Incorporating amino acid PET into routine planning may therefore improve the accuracy of tumor visualization and, ultimately, patient management.

Resultado principalEl resumen no menciona limitaciones.

Apareció: domingo, 8 de noviembre. Nature Communications. Revista con revisión por pares.

DOI: 10.1038/s41467-026-78980-1